Rocket Pharmaceuticals, Inc. (RCKT)
2.18
-0.18
(-7.63%)
USD |
NASDAQ |
Oct 16, 16:00
2.21
+0.03
(+1.38%)
After-Hours: 20:00
Rocket Pharmaceuticals Cash from Investing (Quarterly) : 214.36M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 214.36M |
| March 31, 2026 | 17.45M |
| December 31, 2025 | 36.42M |
| September 30, 2025 | 93.62M |
| June 30, 2025 | 31.76M |
| March 31, 2025 | -58.04M |
| December 31, 2024 | -37.87M |
| September 30, 2024 | 78.92M |
| June 30, 2024 | 55.62M |
| March 31, 2024 | 35.03M |
| December 31, 2023 | -140.80M |
| September 30, 2023 | 48.25M |
| June 30, 2023 | 31.21M |
| March 31, 2023 | -36.72M |
| December 31, 2022 | -108.58M |
| September 30, 2022 | 23.46M |
| June 30, 2022 | 78.79M |
| March 31, 2022 | -63.00M |
| December 31, 2021 | 16.86M |
| September 30, 2021 | -18.19M |
| June 30, 2021 | 49.35M |
| March 31, 2021 | -29.17M |
| December 31, 2020 | -54.46M |
| September 30, 2020 | -64.19M |
| June 30, 2020 | -5.435M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.50M |
| December 31, 2019 | 23.51M |
| September 30, 2019 | 35.18M |
| June 30, 2019 | -126.88M |
| March 31, 2019 | 29.18M |
| December 31, 2018 | 19.05M |
| September 30, 2018 | -2.985M |
| June 30, 2018 | -107.41M |
| March 31, 2018 | 86.08M |
| December 31, 2017 | -0.03M |
| September 30, 2017 | -0.001M |
| June 30, 2017 | -0.598M |
| March 31, 2017 | -0.131M |
| December 31, 2016 | -42.28M |
| September 30, 2016 | 4.931M |
| June 30, 2016 | -16.37M |
| March 31, 2016 | -12.34M |
| December 31, 2015 | -2.24M |
| September 30, 2015 | -29.40M |
| June 30, 2015 | -0.03M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | -93.37M |
| Intellia Therapeutics, Inc. | -141.57M |
| Beam Therapeutics, Inc. | -9.875M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -39.61M |
| Cash from Financing (Quarterly) | 0.15M |
| Free Cash Flow | -170.40M |
| Free Cash Flow Per Share (Quarterly) | -0.346 |
| Free Cash Flow to Equity (Quarterly) | -39.66M |
| Free Cash Flow to Firm (Quarterly) | -39.18M |
| Free Cash Flow Yield | -69.48% |